Matteo Della Porta on the phase 3 COMMANDS trial examining luspatercept versus epoetin alfa in patients with lower-risk myleodysplastic syndrome
de
The Lancet Haematology in conversation with
2024-08-22 22:00:00
Fecha de lanzamiento
08:08
Duración
